Loading people...
Iris Wang is the Founding Partner and Chief Investment Officer at TruMed Investment, based in Hong Kong. She previously served as a Partner at OrbiMed, where she specialized in private equity and venture capital across the Asian life sciences sector and helped deploy capital from the firm's $1.1 billion Asia Partners V fund. Before transitioning to private equity, Wang worked as a Director at Credit Suisse heading the Asia and China healthcare research team, and held strategic management consulting roles at McKinsey and Company and AT Kearney. She holds an MBA from Columbia Business School, where she earned Dean's Honors in Value Investing, alongside a Bachelor of Science in Biological Science and Economics from Peking University. As a CFA charterholder, her current focus centers on directing biotechnology and medical device investments throughout the Asia-Pacific region.
Iris Wang is a distinguished Partner at OrbiMed, a globally recognized investment firm exclusively dedicated to the healthcare sector. As a key member of the OrbiMed team, Iris plays a pivotal role in identifying and executing public equity investments, leveraging her deep industry knowledge and financial acumen to support groundbreaking companies.
At OrbiMed, Iris Wang's investment focus spans a broad spectrum of the healthcare landscape. She is particularly active in the biotechnology, pharmaceutical, and medical device industries. Her work involves rigorous analysis of market trends, scientific advancements, and company fundamentals to pinpoint opportunities that promise significant returns and contribute to medical progress. OrbiMed's investment philosophy emphasizes long-term growth in companies developing innovative therapies, diagnostics, and technologies that address unmet medical needs, and Iris is instrumental in upholding this mission.
Iris Wang's career background is marked by a strong foundation in both science and finance, which uniquely positions her to excel in healthcare investment. While specific details of her early career are typically private, professionals at her level within OrbiMed often possess advanced degrees in life sciences, medicine, or business from top-tier institutions. Prior to joining OrbiMed, she likely honed her analytical and investment skills through roles in equity research, investment banking, or within the healthcare industry itself, gaining invaluable insights into drug development, clinical trials, and market dynamics. This blend of scientific understanding and financial expertise allows her to thoroughly evaluate complex healthcare ventures.
While individual public equity investments are often part of a broader fund strategy and not typically attributed solely to one partner, Iris Wang's involvement contributes to OrbiMed's impressive track record. OrbiMed has a history of investing in companies that have brought transformative treatments to market, from novel cancer therapies to innovative medical devices. Her work supports OrbiMed's commitment to backing companies that are at the forefront of medical innovation, ultimately aiming to improve patient outcomes worldwide. Through her strategic insights and investment decisions, Iris Wang helps shape the future of healthcare by fostering the growth of promising companies within OrbiMed's diverse portfolio.
Iris Wang is a Partner at OrbiMed, a leading global investment firm focused exclusively on the healthcare sector. She specializes in public equity investments within biotechnology, pharmaceuticals, and medical devices.
Iris Wang invests in public equity opportunities within the healthcare sector, with a primary focus on biotechnology, pharmaceuticals, and medical devices. Her work at OrbiMed supports companies developing innovative solutions for unmet medical needs.
Iris Wang works as a Partner at OrbiMed, a prominent global investment firm dedicated to healthcare. OrbiMed has offices in various locations, and she contributes to their worldwide investment strategies.
